Financial Guidance and Company Overview
Antares Immediately Accelerates Halozyme Growth Prospects and
Adds Long-Term Durability of Revenues
PROJECTED REVENUE POTENTIAL
$1B
+%
antares
pharma
+%
Drivers
Current Portfolio
antares®
•
•
Waves 1, 2, 3 and 4 Products
pharma
Halozyme Revenue
Guidance $530-$560M*
2022 Projected
Granted and submitted
co-formulation patents
2027 Potential
+%
+ antares
Drivers
•
Wave 5 ENHANZE® Products
Co-formulation patents
submitted 2022-2027
•
NEW partners/products
using new long IP rHUPH20
*Revenue guidance excludes Antares
Halozyme
Halozyme 2027 Projection based on approved products and assumes global approval and launches of 20 additional products in multiple indications. Includes
projections for subcutaneous versions for targets not currently approved or commercially available. Assumes approved and under review co-formulation
patents, Innovator revenues based on Bloomberg or Evaluate Ltd analyst-based estimates when available. Conversion rates based on Halozyme internal
projections. Royalty revenue projections includes targets selected and not yet disclosed. Projected royalty revenue is not risk-adjusted.
2031 Potential
15View entire presentation